Renaissance Capital logo

Heart Test Laboratories Priced, Nasdaq: HSCS

Developing frontline electrocardiogram devices that screen for heart disease.

Industry: Health Care

Latest Trade: $5.28 -0.28 (-5.0%)

First Day Return: -60.0%

Return from IPO: +30.6%

Industry: Health Care

We are a medical technology company focused on applying innovative AI-based technology to an ECG (also known as an EKG) to expand and improve an ECG’s clinical usefulness. Our objective is to make an ECG a far more valuable cardiac screening tool, particularly in frontline or point-of-care clinical settings. HeartSciences’ first product candidate for FDA clearance, the MyoVista wavECG, or the MyoVista, is a resting 12-lead ECG that is also designed to provide diagnostic information related to cardiac dysfunction which has traditionally only been available through the use of cardiac imaging. The MyoVista also provides conventional ECG information in the same test. Our business model, which involves the use of the MyoVista device and consumables for each test, is expected to be “razor-razorblade” as the electrodes used with the MyoVista are proprietary to HeartSciences, and new electrodes are required for every test performed.
more less
IPO Data
IPO File Date 05/17/2022
Offer Price $4.25
Price Range $4.50 - $5.50
Offer Shares (mm) 1.5
Deal Size ($mm) $6
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
IPO Data
IPO Date 06/14/2022
Offer Price $4.25
Price Range $4.50 - $5.50
Offer Shares (mm) 1.5
Deal Size ($mm) $6
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
Underwriters
The Benchmark Company
Company Data
Headquarters Southlake, TX, United States
Founded 2007
Employees 13
Website www.heartsciences.com

Heart Test Laboratories (HSCS) Performance